Drug profile · INN
ribociclib
KISQALI
ribociclib (KISQALI) is a cyclin-dependent kinase 6 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Drug details — ribociclib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 1
- Programs
- 22
- Data quality
- 0.84
Quick answer
ribociclib (KISQALI) is a cyclin-dependent kinase 6 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclin-dependent kinase 6 inhibitor
Primary target: Cyclin-dependent kinase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is ribociclib?
ribociclib (KISQALI) is a cyclin-dependent kinase 6 inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ribociclib?
KISQALI is a marketed brand name for ribociclib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ribociclib?
ribociclib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.